Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone
Author:
Affiliation:
1. CHAD-Center for Health Technology Assessment and Drug Research; AIBILI-Association for Innovation and Biomedical Research on Light and Image; Coimbra Portugal
2. School of Pharmacy; University of Coimbra; Coimbra Portugal
Publisher
Wiley
Subject
Pharmacology (medical),Epidemiology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/pds.3874/fullpdf
Reference63 articles.
1. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions;Wysowski;Arch Intern Med,2005 Jun 27
2. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets;Clarke;Drug Saf,2006
3. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009;Qureshi;Pharmacoepidemiol Drug Saf,2011 Jul
4. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making;McNaughton;BMJ Open,2014 Jan 15
5. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects;Vandenbroucke;JAMA,2008 Nov 26
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat;Frontiers in Cardiovascular Medicine;2023-11-06
2. The Involvement of CXC Motif Chemokine Ligand 10 (CXCL10) and Its Related Chemokines in the Pathogenesis of Coronary Artery Disease and in the COVID-19 Vaccination: A Narrative Review;Vaccines;2021-10-21
3. The forgotten type 2 diabetes mellitus medicine: rosiglitazone;Diabetology International;2021-06-29
4. Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus;Diabetes Therapy;2021-05-28
5. Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy;Global & Regional Health Technology Assessment;2021-04-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3